Hematologic Cancers News
The FDA has approved Rezlidhia (olutasidenib) to treat patients with IDH1-mutated, relapsed or refractory acute myeloid leukemia.
A patient with a history of HIV presents to the ED with a 3- to 4-week history of vomiting and testicle pain. Can you make the diagnosis?
Consolidation with up to 8 cycles of brentuximab vedotin plus nivolumab appears active in high-risk, relapsed/refractory Hodgkin lymphoma.
Residential racial and economic segregation across US counties is associated with higher cancer mortality, a study suggests.
Researchers demonstrated the feasibility of remote cognitive assessments in patients with hematologic malignancies.
Patients with MCL and CNS involvement had superior survival when treated with ibrutinib rather than chemotherapy.
Breast cancer survivors have an increased risk of breast implant-associated ALCL, but the absolute risk is “extremely low,” according to researchers.
Adding gilteritinib to azacitidine did not improve survival outcomes in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia.
Among patients who did not undergo autologous stem cell transplant, 52.7% advanced to second-line treatment.
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
About 40% of patients with lower-risk myelodysplastic syndromes die of the disease within 5 years, a study suggests.
Researchers have characterized treatment-related adverse events associated with antibody-drug conjugates in clinical trials.
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
The new dosing option was approved based on data from a phase 2/3 trial.
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.